OBJECTIVE
To assess the efficacy and safety of Femegyl skin busters in correcting age-related facial skin changes.
MATERIAL AND METHODS
Twenty female volunteers aged 29-78 years (mean age 52.3±11.08 years) were included in the clinical study. The indicators of age-related skin changes and the facial wrinkle severity indicated moderate age-related changes. All study participants received three treatments of intradermal Femegyl R (Biolift) injections in the face and mental region, except for the periorbital area, where Femegyl M (Bioactive) was injected. The follow-up period was 90 days. The following indicators were studied: skin elasticity (cutometry); skin quality indicators (wrinkles, folds, pigmentation, erythema, skin texture) using the modified descriptive scale; the severity of wrinkles and folds using the MAS photo scale; overall physician and subject satisfaction with treatment outcome using the GAIS scale. All subjects had facial ultrasound and self-assessment of their skin condition performed. Immediate and long-term adverse events were monitored during the study.
RESULTS
After the treatment course, we observed a significant increase in skin elasticity by 10-17%, considerable improvement in skin quality (wrinkles, dyschromia, erythema, texture); reduction of the depth of fine wrinkles in the forehead and the para-orbital area (“crows feet”), some reduction in the severity of skin folds. According to ultrasound, after the treatment course, the dermis thickness increased by 14-71%; and after 90 days of follow-up, an increase in dermis acoustic density was observed. The doctors reported improvement after the first session when assessing the overall treatment effectiveness and the course of treatment (GAIS scale of 1 point). After completing the course, the score increased to 2.25 (with a predominance of “excellent” grades). After 90 days, an “excellent” result was observed in 90% of the participants. The study participants’ self-assessment of facial skin condition showed significant improvement during treatment for all indicators (wrinkles, face shape, firmness, and skin hydration). All reported adverse events were predictable and resolved spontaneously.
DISCUSSION
The results suggest that the treatment course with Femegyl R (Biolift) and Femegyl M (Bioactive) skin boosters stimulates skin metabolism and structural reorganization. These processes are not completed after the last treatment but are prolonged over time (at least 90 days). The observed clinical changes may be related to the collagen-stimulating effect of Femegyl injections shown by previous morphological and histological studies.
CONCLUSION
Skin boosters Femegyl R (Bioactive) and Femegyl M (Biolift) are effective and safe for intradermal injections to correct age-related skin changes.
